Integration of anti-PD-1 antibody into chemotherapeutic regimens improved the outcome of aggressive NK cell leukemia: a single-center retrospective real-world analysis
ANKL still had a poor outcome in the past decade. Integration of anti-PD-1 antibody into chemotherapeutic therapy significantly improved the survival of ANKL. The prolonged survival attributed to PD-1 blockade could provide critical opportunities for patients awaiting HSCT.
Authors
- Kai Shen (ORCID: https://orcid.org/0000-0002-7772-8011)
- Pu Kuang (ORCID: https://orcid.org/0000-0002-1007-6784)
- Yi‐Jen Liao (ORCID: https://orcid.org/0000-0002-9836-1503)
- Hongbing Ma (ORCID: https://orcid.org/0000-0002-1174-4078)
- Ting Niu (ORCID: https://orcid.org/0000-0003-1580-1014)
- Nenggang Jiang (ORCID: https://orcid.org/0009-0003-0261-927X)
- Liping Xie (ORCID: https://orcid.org/0000-0001-6440-0239)
- Jie Ji (ORCID: https://orcid.org/0000-0002-6697-5770)
- Zhigang Liu (ORCID: https://orcid.org/0000-0001-6549-3780)
- Yang Dai (ORCID: https://orcid.org/0000-0003-1489-9080)
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-14
- DOI
- https://doi.org/10.3389/fimmu.2025.1576904
- Citations
- 3
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 2.39
Funders
- Department of Science and Technology of Sichuan Province
- Natural Science Foundation of Sichuan Province